Education
About Us
Working with TipRanks
Follow Us
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Chm-2101 Car-T Cells
Colorectal Cancer, Gastric Cancer, Neuroendocrine Tumors
Phase I/II
Recruiting
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Sep 13, 2023
―
Chm-1101 Car-T Cells
Glioblastoma Multiforme Of Brain
Phase I
Active Not Recruiting
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
Nov 16, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Chimeric Therapeutics Ltd. (CHM) have in its pipeline
CHM is currently developing the following drugs: Chm-2101 Car-T Cells, Chm-1101 Car-T Cells. These drug candidates are in various stages of clinical development as the company works toward FDA approval.